MedTrace Logo

Apolipoprotein (APO)E Genotype, Meal Fatty Acids, Postprandial Lipaemia

NCT01522482 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2012-02-02

No results posted yet for this study

Summary

Cardiovascular disease (CVD) is the greatest cause of morbidity and mortality in the UK. Abnormalities in the concentration and/or composition of lipoproteins (the lipid carrying particles), in particular low density lipoproteins (LDL) in circulation, is one of the most important physiological defects contributing to the development of CVD.

The LDL cholesterol (LDLC) response to fatty acid change is in part mediated by the APOE genotype, with E4 individuals (25% of the UK population) being most responsive to changes in dietary fats, showing greater reductions when low levels of saturated fats or fish oils are consumed and greater increases when high levels of these fats are consumed. Therefore the aims of the present study is to understand the mechanism that regulates the higher LDLC response associated with saturated fatty acids and fish oil consumption in healthy men prospectively recruited based on their APOE genotype.

Conditions

Interventions

DIETARY_SUPPLEMENT

High saturated fat meal

Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.

DIETARY_SUPPLEMENT

Saturated fatty acids and fish oil meal

Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil. The dose of fish oils was equivalent to two portions of oily fish.

DIETARY_SUPPLEMENT

High unsaturated fat meal

Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.

Sponsors & Collaborators

  • Unilever R&D

    collaborator INDUSTRY

  • University of Reading

    lead OTHER

Principal Investigators

  • Julie A Lovegrove, Professor · University of Reading

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-12-31
Completion
2011-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01522482 on ClinicalTrials.gov